Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 866
AVAC’s Guide to AIDS 2024 in Munich
The AIDS 2024 conference occurs on the heels of the PURPOSE 1 PrEP trial announcement. AVAC will be tracking discussion and debate on how to make the full range of PrEP products feasible choices for all people who need and want HIV prevention. We’ll also be following the latest scientific advances, efforts in decolonizing global health, successes in community-led initiatives, and more.
The Lens on LEN
In late June 2024, Gilead Sciences announced an early review of the data of the PURPOSE 1 trial by an
independent monitoring board, which found that injectable lenacapavir (LEN) provided as prevention
was safe and highly effective against HIV. No infections were seen among trial participants those receiving LEN. This advocates’ primer provides further background on the product and trials, raises key questions, and explores next steps.
Prevention Option:
Global HIV Prevention Advocates Call for Accelerated Timeline for Widespread Access to Injectable Lenacapavir for PrEP
A global cadre of HIV prevention advocates is calling for an accelerated timeline for access to the HIV prevention drug lenacapavir. Gilead, the developer of the drug, announced topline results from a large study among cisgender African women on 20 June, followed shortly thereafter with a statement about access.
Prevention Option:
GPP Body of Evidence Webinar Series
Good Participatory Practice Guidelines have been shaping and improving clinical research since 2007. They provide a global reference guide for ethical and effective stakeholder engagement, helping ensure the priorities of trial participants and their communities are centered in clinical trials and broader research agendas.
Prevention Option:
STI Watch Newsletter, July 2024
In the second quarter of this year, there have been exciting new reports and updates on guidelines that could help better inform our efforts and ultimately reduce STIs.
PrEP in Black America (PIBA) and Black Public Health Academy Share Statement on Lenacapavir Results
PrEP in Black America (PIBA) and Black Public Health Academy share statement on results of twice-a-year infectable lenacapavir for PrEP proving efficacious among African cisgender women and what this means for Black communities in the US.
From The Lab To The Jab: Lessons learned and what’s next in HIV vaccine research
On 3 June 2024, AVAC hosted a webinar highlighting its Lab to Jab issue briefs on research and development, production and equitable global access to vaccines. Platforms, Not Pathogens Panelists stressed an intentional, rather than incidental...
Prevention Option:
An Overview of Lenacapavir for PrEP Trials
The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1.
Prevention Option:
Landmark Trial in South Africa and Uganda Finds Twice Yearly HIV Prevention Injection Safe and Highly Effective
Adding additional HIV prevention options means more people may find an option that is right for them. Beyond expanded choice, a twice-yearly injection has the potential to transform the way we deliver HIV prevention to people who need and want it most.
Advocates’ Guide to Doxycycline to Prevent Bacterial STIs (DoxyPEP)
DoxyPEP is a post-exposure prophylaxis used to prevent the acquisition of some bacterial STIs after sex. DoxyPEP is inexpensive, easily tolerated, and widely available. However, questions remain regarding who will benefit most from DoxyPEP and how to implement this strategy broadly to ensure equitable access.
showing 1-10 of 866